 These studies showed increased striatal dopamine release in schizophrenia, which has become one of the most established findings of schizophrenia research and is now being tested as a biomarker for risk to develop schizophrenia in prodromal patients.The work with cortical D1 receptor has provided added rationale for testing D1 agonists in schizophrenia.A new direction for work in her imaging group now is dual diagnosis patients with comorbid schizophrenia and cannabis abuse.